MX2020002442A - Metodo de direccionamiento de exosomas. - Google Patents

Metodo de direccionamiento de exosomas.

Info

Publication number
MX2020002442A
MX2020002442A MX2020002442A MX2020002442A MX2020002442A MX 2020002442 A MX2020002442 A MX 2020002442A MX 2020002442 A MX2020002442 A MX 2020002442A MX 2020002442 A MX2020002442 A MX 2020002442A MX 2020002442 A MX2020002442 A MX 2020002442A
Authority
MX
Mexico
Prior art keywords
targeting
targeting exosomes
extracellular vesicles
exosomes
obtainable
Prior art date
Application number
MX2020002442A
Other languages
English (en)
Inventor
Terry Hermiston
Maxine Bauzon
Jonathan Hardy
Christopher H Contag
Masamitsu Kanada
Original Assignee
Gladiator Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gladiator Biosciences Inc filed Critical Gladiator Biosciences Inc
Publication of MX2020002442A publication Critical patent/MX2020002442A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0631—Mammary cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a un método para el direccionamiento de vesículas extracelulares empleando una molécula que comprende un dominio GLA y vesículas extracelulares obtenidas u obtenibles a partir de un método descrito en la presente descripción.
MX2020002442A 2017-09-05 2018-09-05 Metodo de direccionamiento de exosomas. MX2020002442A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762554530P 2017-09-05 2017-09-05
US201762554533P 2017-09-05 2017-09-05
US201762569411P 2017-10-06 2017-10-06
US201762569403P 2017-10-06 2017-10-06
US201762584565P 2017-11-10 2017-11-10
US201762593014P 2017-11-30 2017-11-30
PCT/US2018/049619 WO2019050998A1 (en) 2017-09-05 2018-09-05 METHOD FOR TARGETING EXOSOMES

Publications (1)

Publication Number Publication Date
MX2020002442A true MX2020002442A (es) 2020-07-13

Family

ID=63714024

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002442A MX2020002442A (es) 2017-09-05 2018-09-05 Metodo de direccionamiento de exosomas.
MX2020002250A MX2020002250A (es) 2017-09-05 2018-09-05 Suministro de cargas utiles a las celulas madre.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020002250A MX2020002250A (es) 2017-09-05 2018-09-05 Suministro de cargas utiles a las celulas madre.

Country Status (14)

Country Link
US (3) US20200407422A1 (es)
EP (3) EP3679127A1 (es)
JP (3) JP2020533976A (es)
KR (2) KR20200050961A (es)
CN (2) CN111051500A (es)
AU (2) AU2018330427A1 (es)
BR (2) BR112020004319A2 (es)
CA (2) CA3074291A1 (es)
IL (2) IL272908A (es)
MX (2) MX2020002442A (es)
PE (2) PE20201462A1 (es)
SG (2) SG11202001536PA (es)
WO (3) WO2019050997A1 (es)
ZA (2) ZA202000650B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193211A (en) 2013-03-15 2022-09-26 Bayer Healthcare Llc Gla domains as targeting agents
CN111491655A (zh) 2017-08-07 2020-08-04 加利福尼亚大学董事会 用于生成安全细胞治疗剂的平台
US20200407422A1 (en) 2017-09-05 2020-12-31 GLAdiator Biosciences, Inc. A method of intracellular delivery
CN110036976B (zh) * 2019-05-08 2021-12-07 华南农业大学 一种阻断鸡禽白血病病毒垂直传播的方法及其应用
CN110423777A (zh) * 2019-07-23 2019-11-08 河南科技大学 无荧光染料标记外泌体及其制备方法
CN110711249B (zh) * 2019-09-19 2020-10-27 北京化工大学 一种溶酶体膜包覆纳米颗粒的制备方法
KR102547446B1 (ko) * 2019-11-29 2023-06-26 서울대학교산학협력단 무표지 폴리다이아세틸렌 리포좀 기반의 엑소좀의 검출 방법
CN111803646B (zh) * 2020-06-04 2022-07-05 苏州大学 一种实体肿瘤联合治疗组合物
US20210393536A1 (en) * 2020-06-23 2021-12-23 Board Of Regents, The University Of Texas System Methods and compositions related to extracellular vesicles
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도
CN112516110B (zh) * 2020-10-13 2022-05-13 北京化工大学 一种细胞膜包覆纳米酶的方法
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
KR102285160B1 (ko) * 2020-12-24 2021-08-03 주식회사 타임바이오 전구세포에서 유래한 다기능성 엑소좀을 포함하는 피부염 예방 또는 치료용 약학적 조성물
CN116421738B (zh) * 2023-02-28 2024-03-19 中国医科大学附属第一医院 捕获抗原的溶瘤病毒及其药物组合与制备和应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
CA2103577A1 (en) 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
BR9306984A (pt) 1992-08-27 1999-01-12 Deakin Res Ltd Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
AU6985594A (en) 1993-06-30 1995-01-24 Bonno Nammen Bouma Protein s deletion variants deficient in c4bp binding activity, but having apc cofactor activity, compositions and therapeutic methods
US5597457A (en) 1995-01-23 1997-01-28 The Regents Of The University Of California System and method for forming synthetic protein crystals to determine the conformational structure by crystallography
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
WO1998029453A1 (fr) 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Medicaments diriges vers la membrane cellulaire
US6093573A (en) 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
IL140700A0 (en) 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
AU5483699A (en) 1998-08-13 2000-03-06 American Home Products Corporation Crystal structure of escherichia coli gdp-fucose synthetase and methods of its use
JP2002523057A (ja) 1998-08-25 2002-07-30 ザ スクリップス リサーチ インスティテュート タンパク質の機能を予測するための方法およびシステム
US6801860B1 (en) 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2002003407A (ja) 2000-06-20 2002-01-09 Medei Sci Puraningu:Kk ハイドロキシアパタイトカルシウム指向性薬物輸送担体
EP1417628A4 (en) 2001-08-14 2007-01-31 Dana Farber Cancer Inst Inc COMPUTER-BASED METHODS FOR DESIGNING MOLECULES
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
NZ544728A (en) 2003-06-19 2009-04-30 Bayer Healthcare Llc Factor VII or VIIa Gla domain variants
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN1863545A (zh) * 2003-08-15 2006-11-15 伊利诺斯大学理事会 Cupredoxin家族多肽在癌症治疗中的用途
JP2007523099A (ja) 2004-02-20 2007-08-16 ノボ　ノルディスク　アクティーゼルスカブ 組み合わせ療法
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
ATE491799T1 (de) 2004-05-26 2011-01-15 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
BRPI0514396A2 (pt) 2004-08-17 2009-05-12 Csl Behring Gmbh polipeptìdeos dependentes de vitamina k modificada
JP5127043B2 (ja) * 2005-01-24 2013-01-23 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ホスファチジルセリンに結合するｆｃ融合構築物およびそれらの治療用途
KR100987547B1 (ko) * 2006-06-01 2010-10-12 가톨릭대학교 산학협력단 냉동보관된 제대혈 줄기세포로부터 초기 세포사를 측정하는조성물, 키트 및 그 방법
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
JP5130580B2 (ja) 2007-01-17 2013-01-30 独立行政法人放射線医学総合研究所 幹細胞における低線量被ばくの検出マーカー、及び該マーカーを用いる幹細胞での低線量被ばくレベルを推定又は検出する方法
EP2147096B1 (en) 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
KR100968839B1 (ko) 2008-02-25 2010-07-09 경북대학교 산학협력단 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도
TWI538916B (zh) * 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
WO2010006136A2 (en) * 2008-07-09 2010-01-14 Mayo Foundation For Medical Education And Research Adenovirus targeting
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
CN102256964A (zh) 2008-10-02 2011-11-23 瑞斯比维特有限公司 p38MAP激酶抑制剂
US8283167B2 (en) 2009-02-11 2012-10-09 Clear Vascular Inc. Preparation of annexin derivatives
RU2563231C2 (ru) 2009-06-25 2015-09-20 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Химерные молекулы фактора vii
CA2787992A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
US20140004601A1 (en) 2010-12-20 2014-01-02 Agency For Science, Technology And Research Method of purifying exosomes
EP2684045B2 (en) 2011-03-09 2023-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods to characterize patients suffering from hemolysis
WO2013011011A2 (en) * 2011-07-18 2013-01-24 Iba Gmbh Method of reversibly staining a target cell
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
TWI497845B (zh) 2012-07-18 2015-08-21 Murata Manufacturing Co Coaxial connector
EP2877211A4 (en) * 2012-07-25 2016-02-10 Salk Inst For Biological Studi REGULATION OF THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES CONTAINING PHOSPHATIDYLSERIN
CA2806896C (en) 2012-09-19 2021-06-15 Georgetown University Targeted liposomes prepared by ethanol injection
MY193211A (en) * 2013-03-15 2022-09-26 Bayer Healthcare Llc Gla domains as targeting agents
SI3604333T1 (sl) 2014-03-11 2021-08-31 Molecular Templates, Inc. Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38
CN106604934A (zh) * 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
CN105457032A (zh) 2014-08-11 2016-04-06 中国人民解放军军事医学科学院毒物药物研究所 靶向癌干细胞的碳纳米管-盐霉素药物递送系统、其制备方法及用途
WO2017118764A1 (en) * 2016-01-07 2017-07-13 Thomas Brocker Novel approaches for the in vivo and in vitro visualization of dying cells
CN105567642B (zh) 2016-02-01 2019-07-12 中国科学院生物物理研究所 一种着色性干皮病人多能干细胞的制备方法
US20200407422A1 (en) 2017-09-05 2020-12-31 GLAdiator Biosciences, Inc. A method of intracellular delivery

Also Published As

Publication number Publication date
CA3074678A1 (en) 2019-03-14
PE20201462A1 (es) 2020-12-17
CN111065733A (zh) 2020-04-24
KR20200050961A (ko) 2020-05-12
IL272908A (en) 2020-04-30
WO2019051002A1 (en) 2019-03-14
MX2020002250A (es) 2020-09-18
JP7365704B2 (ja) 2023-10-20
JP2020533404A (ja) 2020-11-19
US11981723B2 (en) 2024-05-14
US20200407421A1 (en) 2020-12-31
RU2020107182A3 (es) 2022-02-28
BR112020003945A2 (pt) 2020-09-08
JP2020533021A (ja) 2020-11-19
AU2018330427A1 (en) 2020-04-02
CA3074291A1 (en) 2019-03-14
ZA202000650B (en) 2021-02-24
WO2019050997A1 (en) 2019-03-14
US20200407422A1 (en) 2020-12-31
SG11202001536PA (en) 2020-03-30
CN111051500A (zh) 2020-04-21
KR20200050975A (ko) 2020-05-12
PE20201263A1 (es) 2020-11-19
EP3679129A1 (en) 2020-07-15
AU2018328223A1 (en) 2020-03-12
RU2020107182A (ru) 2021-10-06
EP3679127A1 (en) 2020-07-15
JP2020533976A (ja) 2020-11-26
IL272942A (en) 2020-04-30
SG11202001535RA (en) 2020-03-30
BR112020004319A2 (pt) 2020-09-08
EP3679128A1 (en) 2020-07-15
ZA202001012B (en) 2021-03-31
WO2019050998A1 (en) 2019-03-14
US20210062143A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
MX2020002442A (es) Metodo de direccionamiento de exosomas.
PH12019502283A1 (en) Anti-lag3 antibodies
MX2020002659A (es) Vesiculas extracelulares bacterianas.
MX2020002660A (es) Vesiculas extracelulares de prevotella.
ZA201902141B (en) Acid-alpha glucosidase variants and uses thereof
MY191735A (en) Production of steviol glycosides in recombinant hosts
GB201717446D0 (en) Affinity purification of engineering extracellular vesicles
PH12019500376A1 (en) Acid-alpha glucosidase variants and uses thereof
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
MX2017001859A (es) Produccion de glicosidos de esteviol en hospederos recombinantes.
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
MX2018009794A (es) Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019002924A (es) Composiciones purificadas de oligosacaridos de leche humana.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
EP4233880A3 (en) Hnf4a sarna compositions and methods of use
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
MX2019005855A (es) Formulaciones que se pueden pulverizar.
IN2015CH01182A (es)
MX2019013250A (es) 2,3,7-trimetiloct-6-enil acetato y 3,7-dimetil-2-metilen-oct-6-eni l acetato y derivados de estos y su uso como sustancias quimicas aromaticas.
EP3502119A3 (en) Immunomodulating beta-1,6-d-glucans
PH12017501549B1 (en) Peptides for inhibiting angiogenesis
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
MX2020002682A (es) Metodos de dosificacion intranasal de metoclopramida.